AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
AngioDynamics (NASDAQ: ANGO) has received European CE Mark approval for its Auryon Atherectomy System, a revolutionary solid-state laser technology for treating Peripheral Artery Disease (PAD). This approval enables the company to enter the European market, expanding its reach in the global PAD market valued at $1.1 billion.
The Auryon System, which received FDA clearance in 2020, has already treated over 50,000 patients in the US. Clinical studies have shown its effectiveness in treating various lesion types with minimal vessel wall impact. The system uses a 355nm wavelength laser platform, allowing for targeted biological reactions without thermal ablation.
Recent studies, including the PATHFINDER registry, have demonstrated the system's safety and efficacy in treating complex PAD cases, showing significant improvements in patient outcomes.
AngioDynamics, Inc. (NASDAQ: ANGO), a leading medical technology company focused on vascular health and cancer treatment, has announced its participation in two upcoming investor conferences. The company will attend the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12, 2024, and present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 10:00 am.
Investors can access a live webcast of the Canaccord Genuity presentation through the 'Investors' section of AngioDynamics' website. These conferences provide an opportunity for the company to showcase its innovative medical technologies and engage with potential investors.
AngioDynamics reported its fiscal year 2024 Q4 and full-year results, showing pro forma net sales of $71.1 million for Q4 (1.9% YoY growth) and $270.7 million for FY2024 (5.3% YoY growth). The company's Med Tech segment saw strong growth, with Q4 sales up 11.3% YoY to $29.3 million. However, AngioDynamics reported a GAAP net loss of $13.4 million in Q4 and $184.3 million for the full year.
Key highlights include FDA clearance and CE Mark approval for the AlphaVac F18 System for pulmonary embolism treatment, a $15 million share repurchase program, and the completion of several strategic divestitures. The company also initiated a transition to a fully outsourced manufacturing model to drive efficiencies and cost savings.
For fiscal year 2025, AngioDynamics expects net sales between $282-$288 million, representing 4.2-6.4% growth over FY2024.
AngioDynamics, a medical technology company, will report its fiscal 2024 fourth-quarter and full-year financial results on July 16, 2024, before market open. The company focuses on restoring blood flow in the vascular system, expanding cancer treatments, and improving patient quality of life. A conference call to discuss the results will be held at 8:00 a.m. ET on the same day. Dial-in options are available for both domestic and international participants, and the call will be webcast on the AngioDynamics investor website. A replay will be accessible online and via phone until July 23, 2024.
AngioDynamics (NASDAQ: ANGO) has received CE Mark approval in Europe for its AlphaVac F1885 System. This regulatory milestone allows the company to market the mechanical thrombectomy system for non-surgical removal of thrombi or emboli from the pulmonary arteries, aiding in the treatment of pulmonary embolism (PE). The system aims to improve patient outcomes in the EU, where PE has a higher prevalence compared to the U.S. In December 2023, AngioDynamics completed patient enrollment for its U.S.-based APEX-AV trial, which showed significant decreases in RV/LV ratios and clot burdens, with a low Major Adverse Event rate.
AngioDynamics, Inc. presented results from the APEX-AV trial assessing the AlphaVac F1885 System for pulmonary embolism treatment at SCAI 2024 Scientific Sessions. The trial showed significant improvement in right ventricular function, clot burden reduction, and low Major Adverse Event rate. The FDA clearance of the device marks a milestone in interventional medicine.
Summary not available.
Summary not available.
Summary not available.
Summary not available.